274 related articles for article (PubMed ID: 15205195)
1. 5-Fluorouracil incorporation into RNA and DNA in relation to thymidylate synthase inhibition of human colorectal cancers.
Noordhuis P; Holwerda U; Van der Wilt CL; Van Groeningen CJ; Smid K; Meijer S; Pinedo HM; Peters GJ
Ann Oncol; 2004 Jul; 15(7):1025-32. PubMed ID: 15205195
[TBL] [Abstract][Full Text] [Related]
2. Time course of inhibition of thymidylate synthase in patients treated with fluorouracil and leucovorin.
Peters GJ; van Groeningen CJ; van der Wilt CL; Meijer S; Smid K; Laurensse E; Pinedo HM
Semin Oncol; 1992 Apr; 19(2 Suppl 3):26-35. PubMed ID: 1557655
[TBL] [Abstract][Full Text] [Related]
3. Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites.
Johnston PG; Benson AB; Catalano P; Rao MS; O'Dwyer PJ; Allegra CJ
J Clin Oncol; 2003 Mar; 21(5):815-9. PubMed ID: 12610179
[TBL] [Abstract][Full Text] [Related]
4. Thymidylate synthase protein expression in colorectal cancer metastases predicts for clinical outcome to leucovorin-modulated bolus or infusional 5-fluorouracil but not methotrexate-modulated bolus 5-fluorouracil.
Aschele C; Debernardis D; Bandelloni R; Cascinu S; Catalano V; Giordani P; Barni S; Turci D; Drudi G; Lonardi S; Gallo L; Maley F; Monfardini S
Ann Oncol; 2002 Dec; 13(12):1882-92. PubMed ID: 12453856
[TBL] [Abstract][Full Text] [Related]
5. Differential effects of two fluorouracil administration regimens for colorectal cancer.
Matsusaka S; Yamasaki H; Kitayama Y; Okada T; Maeda S
Oncol Rep; 2003; 10(1):109-13. PubMed ID: 12469154
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of phosphonacetyl-L-aspartate, 5-fluorouracil, and leucovorin in patients with advanced cancer.
Hageboutros A; Rogatko A; Newman EM; McAleer C; Brennan J; LaCreta FP; Hudes GR; Ozols RF; O'Dwyer PJ
Cancer Chemother Pharmacol; 1995; 35(3):205-12. PubMed ID: 7805178
[TBL] [Abstract][Full Text] [Related]
7. Effects on DNA and RNA after the administration of two different schedules of 5-fluorouracil in colorectal cancer patients.
Hoshino S; Yamashita Y; Maekawa T; Shirakusa T
Cancer Chemother Pharmacol; 2005 Dec; 56(6):648-52. PubMed ID: 15959779
[TBL] [Abstract][Full Text] [Related]
8. Patterns of elevation of plasma 2'-deoxyuridine, a surrogate marker of thymidylate synthase (TS) inhibition, after administration of two different schedules of 5-fluorouracil and the specific TS inhibitors raltitrexed (Tomudex) and ZD9331.
Ford HE; Mitchell F; Cunningham D; Farrugia DC; Hill ME; Rees C; Calvert AH; Judson IR; Jackman AL
Clin Cancer Res; 2002 Jan; 8(1):103-9. PubMed ID: 11801545
[TBL] [Abstract][Full Text] [Related]
9. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin.
Leichman CG; Lenz HJ; Leichman L; Danenberg K; Baranda J; Groshen S; Boswell W; Metzger R; Tan M; Danenberg PV
J Clin Oncol; 1997 Oct; 15(10):3223-9. PubMed ID: 9336359
[TBL] [Abstract][Full Text] [Related]
10. Decreased folylpolyglutamate synthetase activity in tumors resistant to fluorouracil-folinic acid treatment: clinical data.
Chazal M; Cheradame S; Formento JL; Francoual M; Formento P; Etienne MC; François E; Richelme H; Mousseau M; Letoublon C; Pezet D; Cure H; Seitz JF; Milano G
Clin Cancer Res; 1997 Apr; 3(4):553-7. PubMed ID: 9815719
[TBL] [Abstract][Full Text] [Related]
11. Quantitation of intratumoral thymidylate synthase expression predicts for resistance to protracted infusion of 5-fluorouracil and weekly leucovorin in disseminated colorectal cancers: preliminary report from an ongoing trial.
Leichman L; Lenz HJ; Leichman CG; Groshen S; Danenberg K; Baranda J; Spears CP; Boswell W; Silberman H; Ortega A
Eur J Cancer; 1995; 31A(7-8):1306-10. PubMed ID: 7577041
[TBL] [Abstract][Full Text] [Related]
12. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B
Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase.
Smorenburg CH; Peters GJ; van Groeningen CJ; Noordhuis P; Smid K; van Riel AM; Dercksen W; Pinedo HM; Giaccone G
Ann Oncol; 2006 Jan; 17(1):35-42. PubMed ID: 16251201
[TBL] [Abstract][Full Text] [Related]
14. Regional and systemic therapies for advanced colorectal carcinoma: randomized clinical trial results.
Benson AB
Oncology (Williston Park); 1998 Oct; 12(10 Suppl 7):28-34. PubMed ID: 9830622
[TBL] [Abstract][Full Text] [Related]
15. High-dose 5-Fluorouracil with uridine-diphosphoglucose rescue increases thymidylate synthase inhibition but not 5-Fluorouracil incorporation into RNA in murine tumors.
Codacci-Pisanelli G; Van der Wilt CL; Smid K; Noordhuis P; Voorn D; Pinedo HM; Peters GJ
Oncology; 2002; 62(4):363-70. PubMed ID: 12138245
[TBL] [Abstract][Full Text] [Related]
16. Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors.
Rustum YM; Harstrick A; Cao S; Vanhoefer U; Yin MB; Wilke H; Seeber S
J Clin Oncol; 1997 Jan; 15(1):389-400. PubMed ID: 8996166
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms for 5-fluorouracil resistance in human colon cancer DLD-1 cells.
Inaba M; Naoe Y; Mitsuhashi J
Biol Pharm Bull; 1998 Jun; 21(6):569-73. PubMed ID: 9657039
[TBL] [Abstract][Full Text] [Related]
18. Preliminary observations indicate variable patterns of plasma 5-fluorouracil (5-FU) levels during dose optimization of infusional 5-FU in colorectal cancer patients.
Kline CL; Sheikh HS; Scicchitano A; Gingrich R; Beachler C; Finnberg NK; Liao J; Sivik J; El-Deiry WS
Cancer Biol Ther; 2011 Oct; 12(7):557-68. PubMed ID: 21931273
[TBL] [Abstract][Full Text] [Related]
19. Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: implications for treatment with fluorouracil.
Peters GJ; van der Wilt CL; van Groeningen CJ; Smid K; Meijer S; Pinedo HM
J Clin Oncol; 1994 Oct; 12(10):2035-42. PubMed ID: 7931471
[TBL] [Abstract][Full Text] [Related]
20. Biochemical modulation of 5-fluorouracil with leucovorin or delayed uridine rescue. Correlation of antitumor activity with dosage and FUra incorporation into RNA.
Nord LD; Stolfi RL; Martin DS
Biochem Pharmacol; 1992 Jun; 43(12):2543-9. PubMed ID: 1378737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
